55 /100
HIGH RISK
Score updated Jul 14, 2026

PBM — Psyence Biomedical Ltd. Dilution Risk Tracker

Track PBM dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track PBM — Get alerts when the score changes →

As of July 14, 2026, Psyence Biomedical Ltd. (PBM) has a DilutionWatch DilutionScore of 55/100, rated HIGH dilution risk. Psyence Biomedical Ltd. has a market capitalization of $9.52M, 2.29M shares outstanding, 5 institutional holders tracked.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
40
📊 Float Risk
85
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for PBM.
🔔 Track PBM — Get forecast alerts →

💹 Market Data

Market Cap$9.52M
Shares Outstanding2.29M
Float292.7K
Cash$7.15M
DebtN/A
Short InterestN/A

🏛 Institutional Holdings

5 institutional holders · 158.0K shares
#1 Parallel Advisors, LLC 151.2K shares
#2 Stonehage Fleming Financial Services Holdings Limited 89 shares

📉 Short Interest

Short Interest36.0K
Days to Cover1.0
% of Float12.3%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

13F-HR BENEFICIAL OWNERSHIP Mar 31, 2026
13F-HR BENEFICIAL OWNERSHIP Mar 31, 2026
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

📋 What This Means for PBM Shareholders

Psyence Biomedical Ltd. (PBM) has a DilutionScore of 55/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch's EDGAR monitoring for PBM shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for PBM in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for PBM alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track PBM Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking PBM — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for PBM
📊 PBM FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 PBM Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.